Keywords: lorus, therapeutics, gti, seeks, clearance, begin, trials
Lorus Therapeutics' GTI 2040 seeks clearance to begin US trials
Article | 24 November 1999
Lorus Therapeutics says it has seen "dramatic" results, includingcomplete remissions, with its anticancer agent GTI 2040 in combination with 5-fluorouracil or ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
